Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Edap Tms Sa ADR (NQ: EDAP )

6.840 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 6.840
Bid (Size) 5.350 (25)
Ask (Size) 8.500 (30)
Prev. Close 6.840
Today's Range 6.840 - 6.840
52wk Range 3.600 - 12.23
Shares Outstanding 37,103,779
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
EDAP Announces Final Results from HIFI Study Comparing Outcomes of Focal One® HIFU Versus Radical Prostatectomy to be Presented During Plenary Session at the Upcoming 119th American Urological Association (AUA) Annual Meeting
From EDAP TMS S.A.
Via GlobeNewswire
EDAP Stock Earnings: Edap TMS Misses EPS, Beats Revenue for Q4 2023
EDAP stock results show that Edap TMS missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace

Performance

YTD
+28.81%
+28.81%
1 Month
-7.57%
-7.57%
3 Month
+9.09%
+9.09%
6 Month
+0.29%
+0.29%
1 Year
-37.02%
-37.02%

More News

Read More
EDAP Reports Fourth Quarter and Full-Year 2023 Financial Results
From EDAP TMS S.A.
Via GlobeNewswire
Earnings Outlook For Edap TMS
Via Benzinga
Recap: Edap TMS Q3 Earnings
Via Benzinga
Edap TMS's Earnings Outlook
Via Benzinga
Earnings Scheduled For March 27, 2024
Via Benzinga
EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024
From EDAP TMS S.A.
Via GlobeNewswire
EDAP to Present at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
From EDAP TMS S.A.
Via GlobeNewswire
EDAP Announces FDA Breakthrough Device Designation for Focal One® in the Treatment of Deep Infiltrating Rectal Endometriosis
From EDAP TMS S.A.
Via GlobeNewswire
EDAP Announces Record Preliminary Fourth Quarter and Full-Year 2023 Revenues
From EDAP TMS S.A.
Via GlobeNewswire
EDAP Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One HIFU Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis
From EDAP TMS S.A.
Via GlobeNewswire
EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements
From EDAP TMS S.A.
Via GlobeNewswire
EDAP Appoints Ken Mobeck, Global Chief Financial Officer, and Francois Dietsch, Global Chief Accounting Officer
From EDAP TMS S.A.
Via GlobeNewswire
EDAP Announces Positive Opinion for Reimbursement from the French National Authority for Health (HAS) for HIFU treatment of Prostate Cancer
From EDAP TMS S.A.
Via GlobeNewswire
EDAP Appoints Lance Willsey, M.S., M.D. to Board of Directors
From EDAP TMS S.A.
Via GlobeNewswire
EDAP Receives 2023 Industry Category Award from the French National Institute for Intellectual Property (INPI) for Its Therapeutic Ultrasound Technology
From EDAP TMS S.A.
Via GlobeNewswire
EDAP to Present at Piper Sandler’s 35th Annual Healthcare Conference
From EDAP TMS S.A.
Via GlobeNewswire
EDAP Announces Third Quarter 2023 Financial Results
From EDAP TMS S.A.
Via GlobeNewswire
EDAP to Present at the Jefferies London Healthcare Conference
From EDAP TMS S.A.
Via GlobeNewswire
EDAP TMS SA to Announce Third Quarter 2023 Financial Results on November 9, 2023
From EDAP TMS S.A.
Via GlobeNewswire
EDAP to Present at Morgan Stanley Annual Global Healthcare Conference and the H.C. Wainwright Annual Global Investment Conference
From EDAP TMS S.A.
Via GlobeNewswire
EDAP Announces Second Quarter 2023 Financial Results
From EDAP TMS S.A.
Via GlobeNewswire
EDAP TMS SA to Announce Second Quarter 2023 Financial Results on August 24, 2023
From EDAP TMS S.A.
Via GlobeNewswire
EDAP Announces Reimbursement Approval in Switzerland for the Use of High-Intensity Focused Ultrasound (HIFU) in the Treatment of Prostate Cancer
From EDAP TMS S.A.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.